According to the official website of the Zhejiang Securities Regulatory Bureau, shulan medical management co., ltd. (hereinafter referred to as "shulan medical") recently disclosed the public documents for the counseling filing, and intends to sprint for the A-share IPO, with CICC acting as its listing counseling agency.
According to the counseling filing documents, Shulan Medical was established in November 2013 and changed into a joint-stock company in December 2020, which is a comprehensive technology medical group integrating health and medical services, medical research, medical education and life science and technology, and currently has Medical institutions such as Shulan (Hangzhou) Hospital, Shulan (Anji) Hospital, and Shulan Liangzhu International Medical Center (preparing). In addition, Shulan Medical also cooperates with medical institutions in Fujian, Hainan, Chongqing, Zhengzhou and other places to assist local medical institutions to establish high-quality medical platforms.
At the same time, Shulan Medical said that it actively explores in the field of digital health, builds a group-wide medical cloud platform, and creates a data-driven closed loop of clinical service processes.
In addition, the above documents show that the actual controller of Shulan Medical is Zheng Jie, who is currently the president of Shulan Medical, the executive vice president of Zhejiang Digital Medical and Health Technology Research Institute, the initiator of OMAHA (Open Medical and Health Alliance), the vice president of the Hospital Management Branch of the China Association of Non-public Medical Institutions, and the vice chairman of the Digital Medicine Branch of the Zhejiang Medical Association.
Inquiry into public information shows that Zheng Jie is the son of Li Lanjuan and Zheng Shusen, his mother Li Lanjuan is the leader of the national infectious disease key discipline and an academician of the Chinese Academy of Engineering, and his father Zheng Shusen is an expert in hepatobiliary surgery and liver transplantation, and is also an academician of the Chinese Academy of Engineering and a foreign academician of the French National Academy of Medical Sciences.
It is worth mentioning that Zheng Shusen is currently the director of Shulan Medical, and Li Lanjuan once served as the chairman of Shulan Medical, stepping down from this position on December 1, 2020, in addition, Li Lanjuan and Zheng Shusen also appeared in the mentor lineup list of Shulan Medical's official website, so Shulan Medical was also interpreted by the market as an attempt to "academician medical treatment".
As of the date of the counseling filing report, Shulan Medical has a total of 31 shareholders.
Among them, Shanghai Shulan Investment Co., Ltd., with a capital contribution ratio of 46.9067%, is the largest shareholder; Cliff Investment Pte. Ltd. 13.9337% of the capital contribution, the company is managed by GIC Special Investments Pte Ltd (Singapore Government Direct Investment Co., Ltd.), a natural person Ge Feiyu 5.2936%, China Life (Shanghai) Health Industry Equity Investment Center (limited partnership) 4.7506%, Ningbo Meishan Bonded Port Area Mingshang Investment Management Partnership (Limited Partnership) 3.1877%, the top five shareholders.
In addition, the 21st Century Business Herald reporter combed and found that well-known investment institutions such as Yida Capital, Qiming Venture Capital, Sequoia Capital, PICC Capital, Shanghai Pharmaceutical (601607.SH/02607.HK) and Shanghai Ruili Innovation Equity Investment Fund Partnership (Limited Partnership) initiated the establishment of Shanghai Health and Medical Industry Equity Investment Fund Partnership (Limited Partnership), DT Capital, Puhua Capital, Galaxy Yuanhui Investment Co., Ltd., a wholly-owned subsidiary of China Galaxy (601881.SH/06881.HK), appears in the list of shareholders of Shulan Medical.
According to the counseling plan, CICC will start counseling Shulan Medical in April 2021, and the counseling plan will be implemented in three phases, the first phase is April 2021, the second phase is from May 2021 to June 2021, and the third phase is from July 2020 to the counseling acceptance. The specific counseling time will be adjusted according to the requirements of the CSRC and the Zhejiang Securities Regulatory Bureau and the actual situation of Shulan Medical.
For more information, please download the 21 Finance APP